The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Healthcare drags FTSE 100 down; Vodafone jumps

Wed, 03rd Feb 2021 09:17

(For a Reuters live blog on U.S., UK and European stock
markets, click LIVE/ or type LIVE/ in a news window)

* GlaxoSmithKline slumps on COVID-19 vaccine development

* Vodafone gains after earnings beat estimates

* Glencore rises after maintaining 2021 output targets

* FTSE 100 down 0.1%, FTSE 250 adds 0.3%
(Updates to close)

By Shashank Nayar, Amal S and Shivani Kumaresan

Feb 3 (Reuters) - The FTSE 100 slipped on Wednesday, as
falls in healthcare stocks offset gains elsewhere driven by
investors' hopes that mass vaccinations would accelerate an
economic revival, while Vodafone jumped after its earnings beat
estimates.

GlaxoSmithKline Plc lost 6.3% and was the biggest
drag on the index, after warning of a bigger than expected fall
in 2021 earnings as the COVID-19 pandemic continues to disrupt
other areas of healthcare.

"GSK's expected new dividend policy will mean lower payouts,
and thus the stock, a noted income stream for investors, has
taken a knock, with fears that AstraZeneca might have to follow
suit, leading to a small decline for that company’s shares too,"
said Chris Beauchamp, chief market analyst at IG.

The blue-chip FTSE 100 index slid 0.1%, with
AstraZeneca Plc, Smith & Nephew plc and Hikma
Pharmaceuticals also weighing on the index, while the
mid-cap index added 0.3%.

The export-oriented and commodity stocks-heavy FTSE 100 has
rebounded from early-2021 losses to trade 1.3% higher for the
year, as vaccinations pick up pace, corporate earnings improve
and commodity prices increase.

A survey indicated that Britain's third national coronavirus
lockdown has put the economy on course for a sharp contraction
in early 2021, but services companies - buoyed by progress on
vaccinations - are confident about recovery.

Britain's health minister on Wednesday defended his decision
to give a shot developed by Oxford University and AstraZeneca to
all age groups including over-65s, saying this was supported by
scientific evidence.

Vodafone, the world's second-largest mobile
operator, rose 5.9% and was the top boost to the FTSE 100 after
saying its organic service revenue returned to growth in its
third quarter, beating analysts' expectations.

Glencore, which mines coal, nickel, silver, zinc
and copper, added 0.9% after affirming all of its production
targets for 2021.
(Reporting by Shashank Nayar and Shivani Kumaresan in
Bengaluru; editing by Uttaresh.V and Kevin Liffey)

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.